Found: 16
Select item for more details and to access through your institution.
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
- Published in:
- Human Psychopharmacology: Clinical & Experimental, 2013, v. 28, n. 2, p. 124, doi. 10.1002/hup.2289
- By:
- Publication type:
- Article
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
- Published in:
- Movement Disorders, 2015, v. 30, n. 7, p. 919, doi. 10.1002/mds.26170
- By:
- Publication type:
- Article
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2014, v. 52, n. 8, p. 631, doi. 10.5414/CP202091
- By:
- Publication type:
- Article
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2013, v. 51, n. 12, p. 976, doi. 10.5414/CP201970
- By:
- Publication type:
- Article
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 363, p. 1, doi. 10.1126/scitranslmed.aad9704
- By:
- Publication type:
- Article
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 15, p. 5188, doi. 10.3390/ijms21155188
- By:
- Publication type:
- Article
Asenapine pharmacokinetics and tolerability in a pediatric population.
- Published in:
- Drug Design, Development & Therapy, 2018, v. 12, p. 2677, doi. 10.2147/DDDT.S171475
- By:
- Publication type:
- Article
Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 8, p. 1408, doi. 10.1111/cts.13541
- By:
- Publication type:
- Article
α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis.
- Published in:
- Journal of Neuroscience, 2006, v. 26, n. 46, p. 24, doi. 10.1523/JNEUROSCI.3821-06.2006
- By:
- Publication type:
- Article
α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration.
- Published in:
- Journal of Neuroscience, 2006, v. 26, n. 36, p. 9304, doi. 10.1523/JNEUROSCI.0519-06.2006
- By:
- Publication type:
- Article
Lipid Rafts Mediate the Synaptic Localization of α-Synuclein.
- Published in:
- Journal of Neuroscience, 2004, v. 24, n. 30, p. 6715, doi. 10.1523/JNEUROSCI.1594-04.2004
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 5, p. 1234, doi. 10.1002/cpt.1258
- By:
- Publication type:
- Article
Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 10, p. 1093, doi. 10.1002/jcph.523
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects.
- Published in:
- CTS: Clinical & Translational Science, 2019, v. 12, n. 5, p. 545, doi. 10.1111/cts.12645
- By:
- Publication type:
- Article
Safety and pharmacokinetics of single ascending doses of TAK‐594/DNL593, a brain‐penetrant progranulin replacement therapy, in healthy volunteers: Interim results from Part A of a Phase 1/2 clinical trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.075068
- By:
- Publication type:
- Article